



SUPPLEMENTARY FIG. S5. Oligonucleotides contained three central mismatches, and scrambled sequences (12.5 nM) do not activate *FXN* mRNA expression in patient-derived GM03816 cells (330/380). CM-PO 1 and CM-PO 2 are two biological replicates of compound CM-PO, NT is no treatment (no oligos and no lipid “RNAiMAX”) control, MM1–3 are three central mismatch controls.